Medications Post-CABG
All patients undergoing CABG should be started on aspirin 75-100 mg daily within 6 hours postoperatively and continued indefinitely, along with high-intensity statin therapy initiated immediately to achieve LDL-C <100 mg/dL (ideally <55 mg/dL), unless contraindications exist. 1, 2
Core Medication Regimen
Antiplatelet Therapy
Aspirin is the cornerstone:
- Start aspirin 100-325 mg within 6 hours after surgery if not already given preoperatively 1
- Continue 75-100 mg daily indefinitely to reduce saphenous vein graft closure and adverse cardiovascular events 2
- This is a Class I, Level A recommendation with the strongest evidence for graft patency 3, 4
For aspirin-intolerant patients:
- Clopidogrel 75 mg daily is a reasonable alternative 1
Dual antiplatelet therapy (DAPT) considerations:
- If CABG was performed in the context of recent ACS (acute coronary syndrome), consider adding clopidogrel 75 mg to aspirin for up to 12 months 3, 5
- The evidence for routine DAPT post-CABG in stable patients is weak and not generally recommended 6, 7
- DAPT may increase bleeding risk without clear benefit in graft patency for routine CABG patients 8
Lipid Management
Statin therapy is mandatory:
- All patients must receive statin therapy unless contraindicated (Class I, Level A) 1
- Target LDL-C <100 mg/dL with at least 30% reduction from baseline 1
- For very high-risk patients, target LDL-C <55 mg/dL (1.4 mmol/L) with ≥50% reduction 2
- Start high-intensity statin immediately, even for urgent/emergency CABG if not already on therapy 1
- If goals not met with maximum tolerated statin dose, add ezetimibe 2
The evidence shows statins reduce perioperative mortality, stroke, atrial fibrillation, and improve long-term graft patency 9. A Swedish registry study of 28,812 CABG patients demonstrated statins were associated with 44% lower mortality risk (HR 0.56) 10.
ACE Inhibitors/ARBs
Indications for ACE inhibitors:
- Mandatory for patients with LVEF <40% (Class I, Level A) 4
- Mandatory for patients with hypertension, diabetes, or chronic kidney disease (Class I, Level A) 4
- Consider for all other patients (Class I, Level B) 4
- May be optional in lower-risk patients with normal LVEF and well-controlled risk factors 4
For ACE inhibitor-intolerant patients:
- Use ARBs in patients with heart failure or MI with LVEF <40% (Class I, Level A) 4
The Swedish registry showed RAAS inhibitors were associated with 22% lower mortality risk (HR 0.78) 10.
Beta-Blockers
The role of beta-blockers is controversial:
- Traditionally recommended for most patients 4
- Recent evidence questions routine use - the Swedish registry found no mortality benefit (HR 0.97, p=0.54) 10
- Definite indications: heart failure with reduced ejection fraction, prior MI with LV dysfunction, or symptomatic angina
- For patients without these specific indications, beta-blockers may be optional
Additional Considerations
Anticoagulation
- Only indicated for specific conditions: atrial fibrillation, prosthetic heart valve, LV thrombus, or venous thromboembolism 3
- When warfarin is needed with aspirin, use low-dose aspirin 75-81 mg daily and monitor closely for bleeding 3
- Prefer DOACs over warfarin when eligible 2
Diabetes Management
- Target HbA1c ≤7% with individualized approach 3
- Metformin is effective first-line therapy if not contraindicated 3
- Intensive lifestyle modifications including daily physical activity and weight management 3
Blood Pressure Control
- Aggressive management of hypertension is essential 4
- Target BP <130/80 mmHg in most patients
Critical Implementation Points
Common pitfalls to avoid:
- Delaying aspirin initiation - must start within 6 hours postoperatively 1
- Inadequate statin dosing - use high-intensity statins, not moderate doses 1
- Stopping medications prematurely - aspirin and statins are lifelong unless contraindicated
- Forgetting cardiac rehabilitation - strongly recommended for all patients to improve mortality 11
Medication adherence:
- The Swedish registry showed medication use declined significantly over time (statins from 93.9% at 6 months to 77.3% at 8 years) 10
- Regular follow-up and patient education are essential to maintain adherence
Cardiac rehabilitation:
- Strongly recommended for all CABG patients (Class I, Level A) 11
- Improves cardiovascular mortality by 20% and overall mortality 11
- Only 31% of eligible patients receive CR - referral is a critical gap 11
Monitoring and Follow-up
- Check lipid panel 4-12 weeks after statin initiation
- Monitor renal function and potassium if on ACE inhibitors/ARBs
- Assess medication adherence at every visit
- Screen for and aggressively treat depression, which affects 20-30% of CABG patients 1
- Ensure smoking cessation counseling - critical for outcomes 11